BlackRock Discloses Passive Stake in UroGen Pharma
Ticker: URGN · Form: SC 13G · Filed: Feb 2, 2024 · CIK: 1668243
| Field | Detail |
|---|---|
| Company | Urogen Pharma Ltd. (URGN) |
| Form Type | SC 13G |
| Filed Date | Feb 2, 2024 |
| Risk Level | low |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, passive-investment, SC-13G
TL;DR
**BlackRock just revealed a big, passive stake in UroGen Pharma.**
AI Summary
BlackRock Inc., a major investment firm, filed an SC 13G on February 2, 2024, disclosing its ownership of UroGen Pharma Ltd. common stock as of December 31, 2023. This filing indicates that BlackRock holds a significant, passive stake in UroGen Pharma, a pharmaceutical company. For investors, this matters because large institutional ownership by a firm like BlackRock can signal confidence in the company's long-term prospects and potentially provide a degree of stability to the stock price.
Why It Matters
This filing shows a major institutional investor, BlackRock, has a significant, passive stake in UroGen Pharma, which can be seen as a vote of confidence.
Risk Assessment
Risk Level: low — This filing indicates a passive investment by a large institution, which generally reduces risk by signaling stability rather than an activist position.
Analyst Insight
An investor might view BlackRock's passive stake as a positive signal, suggesting institutional confidence, and could consider further research into UroGen Pharma's fundamentals.
Key Players & Entities
- BlackRock Inc. (company) — reporting person, institutional investor
- UroGen Pharma Ltd. (company) — subject company, pharmaceutical preparations
- December 31, 2023 (date) — date of event requiring filing
- February 2, 2024 (date) — filing date
Forward-Looking Statements
- BlackRock will maintain its passive stake in UroGen Pharma Ltd. for the foreseeable future. (BlackRock Inc.) — medium confidence, target: December 31, 2024
FAQ
What type of filing is this document?
This document is an SC 13G filing, specifically designated under Rule 13d-1(b) of the Securities Exchange Act of 1934.
Which company is the subject of this filing?
The subject company of this filing is UroGen Pharma Ltd., with Central Index Key (CIK) 0001668243.
Who is the reporting person in this SC 13G filing?
The reporting person is BlackRock Inc., with Central Index Key (CIK) 0001364742.
What is the 'Date of Event Which Requires Filing of this Statement'?
The 'Date of Event Which Requires Filing of this Statement' is December 31, 2023.
What is the SEDOL Number for UroGen Pharma Ltd.'s Common Stock?
The SEDOL Number for UroGen Pharma Ltd.'s Common Stock is BZ7PJQ1.
Filing Details
This Form SC 13G (Form SC 13G) was filed with the SEC on February 2, 2024 regarding UroGen Pharma Ltd. (URGN).